Foresite Capital — Full Portfolio

BiotechHayward, US

Roger M. Perlmutter(Executive Officer, Director)

BoardJoshua Wolfe(Director)inDror Berman(Director)Leon Chen(Director)Adam Goulburn(Director)in

Board seatJames Tananbaum· per SEC Form D

Co-investorsLux CapitalDimension Capital

BiotechCambridge, US

Robert Gould(Executive Officer, Director)

BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsThird Rock Ventures

Next-generation genetic sequencing using microfluidics for sequencing and molecular diagnostics

BiotechPleasanton, US

Brad Crutchfield(Chief Commercial Officer)Jean Philibert(Chief People Officer)Ben Hindson(Chief Scientific Officer, President)Eric S Whitaker(General Counsel)Justin McAnear(Chief Financial Officer)Serge Saxonov(Chief Executive Officer)

Co-investorsFoothill VenturesKhosla VenturesPaladin Capital GroupVenrock

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)

Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalRA CapitalSofinnova VenturesSofinnova Venture Partners+1 more

BiotechAbingdon, Oxfordshire

David Mott(Director)Ali Behbahani(Director)Peter Thompson(Director)Elliott Sigal(Director)Dr. Jonathan Knowles(Chairman)James Noble(Chief Executive Officer)

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Executive Officer, Director)Harlan Robins(Executive Officer)inKathleen Determann(Executive Officer)Dean Schorno(Executive Officer)Chris Carlson(Executive Officer)

BoardArnold Levine(Director)

Co-investorsDecheng CapitalFMG CapitalKhosla VenturesOrbiMed

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)

BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)Erez Chimovits(Director)in

Co-investorsOrbiMedPontifax Venture CapitalQuan CapitalaMoonNovartis Venture Fund

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsMission Bay CapitalMission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)

BoardOWEN WITTE(Director)

Co-investorsAvoro Capital AdvisorsTPGVida Ventures

ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.

BiotechHealthtech

Co-investorsage1Lightstone VenturesvenBio Partners

Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.

BiotechHealthtechWarminster, US

William H. Collier(President and Chief Executive Officer)Gaston Picchio(Chief Development Officer)Michael J. McElhaugh(Chief Business Officer)David C. Hastings(Chief Financial Officer)Michael J. Sofia(Chief Scientific Officer)Elizabeth Howard(Executive Officer)

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos, Ph.d.(President and Treasurer)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)

Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesJazzya InvestmentsMedicxiMyelin VC+4 more

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalGV (Google Ventures)HongShan Capital Group+1 more

Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalPremji InvestRA CapitalRed Tree Venture+1 more

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells.

BiotechHealthtechBeijing

Chunhua Wang(Chief Operating Officer)Wei Gao(General Counsel)Hai Huang(Global Chief Commercial Officer)Alexander A. Zukiwski(Chief Medical Officer)Wei (Larry) Zhang(President)Wei-Wu He(Chief Executive Officer, Chairman of the Board of Directors)

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.

BiotechHealthtechHampton, US

Anthony S. Marucci(Executive Officer, Director)Avery W. Catlin(Executive Officer)Timothy M. Shannon, M. D.(Director)

BoardRichard van den Broek(Director)Herbert J. Conrad(Director)Karen Shoos(Director)

CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.

BiotechHealthtech

Co-investorsDecheng CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+2 more

Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)Errik Anderson(Executive Officer, Director)Steve Tregay(Director)

Co-investorsBioBritF-Prime CapitalOrbiMedvenBio PartnersVivo Capital

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen F. Betz(Executive Officer)YunFei Zhu(Executive Officer)

BoardMahendra Shah(Director)Steve Kaldor(Director)Mason Freeman(Director)

Co-investorsVivo Capital

Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers.

BiotechHealthtech

Co-investorsNextech InvestBiotechnology Value FundOrbiMed

Cytokinetics is a biopharmaceutical company focused on muscle biology, developing small molecule muscle activators and inhibitors to treat diseases involving compromised muscle function, including heart failure, hypertrophic cardiomyopathy, and neuromuscular diseases.

BiotechHealthtech

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Director)Ryan Watts(Executive Officer, Director)Alexander O. Schuth(Executive Officer)Carole Ho(Executive Officer)Steve E. Krognes(Director)

BoardDavid P. Schenkein(Director)in

Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalGV (Google Ventures)

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesFrazier Life SciencesOrbiMed

Boulder, US

Kevin Koch(Executive Officer, Director)Alan Russell(Director)Kenneth Harrison(Director)

BoardPeter Thompson(Director)Jonathan Root(Director)

GH Research is a clinical-stage pharmaceutical company developing mebufotenin (5-MeO-DMT) based therapies for psychiatric and neurological disorders.

BiotechDigital HealthMental Health

Co-investorsRA Capital

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)

Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+8 more

Hinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions.

Digital HealthHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Gabriel Mecklenburg(Executive Officer, Director)inDaniel Perez(Executive Officer, Director)

Co-investors11.2 CapitalAlkeon InnovationBessemer Venture PartnersCannage CapitalCoatue ManagementDuke Capital Partners+8 more

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will LewisinGeoffrey Allanin

Co-investorsBessemer Venture PartnersF-Prime CapitalOrbiMedProspect Venture PartnersNVIDIA

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)

Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 Capital

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life SciencesMRL Ventures FundPremji Invest

BiotechLexington, US

Jasbir S. Seehra(Executive Officer, Director)

BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)

Co-investorsArkin CapitalOrbiMed

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TROY WILSON(Executive Officer, Director)PINGDA REN(Executive Officer)YI LIU(Executive Officer)Troy Wilson(Founder)inHEIDI HENSON(Executive Officer)ANNETTE NORTH(Executive Officer)

Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalNextech InvestOUP (Osage University Partners)

BiotechFort Washington, US

Rebecca Taub(Executive Officer, Director)Fred B. Craves(Director)Marc R. Schneebaum(Executive Officer)Keith R. Gollust(Director)Kenneth M. Bate(Director)Richard S. Levy(Director)

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen HorowitzARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)Janus Henderson InvestorsVenrock Healthcare Capital Partners

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in

Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesHarmony PartnersLightspeed Venture PartnersRA Capital+1 more

BiotechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)David C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)Shane Kovacs(Executive Officer)

Omeros is a biopharmaceutical company developing small-molecule and protein therapeutics aimed at diseases with significant unmet medical needs.

BiotechHealthtech

Co-investorsSPRINGROCK VENTURES

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)

Co-investorsARCH Venture PartnersCatalio Capital Management, LPFrazier Life SciencesGeneral CatalystNextech InvestRA Capital+5 more

BiotechSouth San Francisco, US

Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)Brendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)Kristen Gafric(Executive Officer)

Co-investorsSofinnova Partners

Improving patients' lives by accelerating development and commercialization of medicines that matter.

BiotechCambridge, US

Sanjiv K. Patel(Executive Officer, Director)Donald A. Bergstrom(Executive Officer)Thomas Catinazzo(Executive Officer)Peter Rahmer(Executive Officer)Sekar Kathiresan(Director)Douglas S. Ingram(Director)

Co-investorsCommonweal VenturesCurie.Bio

Co-investorsBain Capital Life Sciences

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Co-investorsBain Capital Life SciencesNextech InvestThird Rock Ventures

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)

BoardJavier Perez-Sala(Director)Jan Bonel(Director)

Co-investorsFlying L PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalRA CapitalVisionary Ventures+1 more

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)Charles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)Jean-Yves Nothias(Director)

Co-investorsDecheng Capital

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)

BoardJames I. Healy(Director)

Co-investorsARCH Venture PartnersHAWKTAILPureTech HealthSofinnova Ventures

BiotechLondon

James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)

Co-investorsMC Healthcare VenturesNextech InvestVivo Capital

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Stephen DiPalma(Executive Officer)Alexander (Bo) Cumbo(Executive Officer, Director)Carl Morris(Executive Officer)Martin Freed(Director)Paul Herizch(Executive Officer)Robert Huffines(Director)

Co-investorsBain Capital Life SciencesRA Capital

BiotechWaltham, US

John Pallies(Executive Officer)Arlene Morris(Executive Officer, Director)

BoardDennis Podlesak(Director)Ivor Royston(Director)Luke Evnin, Ph.D.(Director)Kim Kamdar, Ph.D(Director)

Co-investorsPappas CapitalSofinnova VenturesvenBio Partners

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Co-investorsNextech InvestNSG VenturesThird Rock Ventures

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in

Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Frazier Life SciencesLongitude CapitalRA Capital

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)

Co-investorsBessemer Venture PartnersCardinal PartnersLightstone VenturesLongwood FundOberland CapitalOrbiMed

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore

Takeshi Wada(Director)Tan Ping Ping(Executive Officer)Paul B. Bolno, M.D.(Executive Officer, Director)Gregory L. Verdine(Director)Ken Takanashi(Director)Masaharu Tanaka(Director)

Co-investorsRA Capital

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)

Board seatMichael Rome· per SEC Form D

Co-investorsAtlas VentureThe Column GroupARCH Venture PartnersDecheng Capital

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

Dr Mark Kotter(Founder)Przemek Obloj(CEO)Emma Pepperellin

Co-investorsBlueYard CapitalARCH Venture PartnersDynamk CapitalGood AI CapitalHAWKTAILMetaplanet+2 more

Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.

BiotechDeep TechHealthtech

Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)

Co-investorsGV (Google Ventures)Dementia Discovery FundSV Life SciencesDementia DiscoveryLightstone VenturesSV Health Investors+2 more

HealthVerity operates a healthcare and consumer data ecosystem that enables HIPAA-compliant synchronization and exchange of real-world data across pharma, payers, and government agencies.

Data & InfrastructureEnterprise SoftwareHealthtechPhiladelphia, US

Andrew Kress(Co-Founder and CEO)inAndrew Goldberg(Co-Founder and COO)

BoardMichael Greeley(Director)inRachel Winokur(Director)

Co-investorsFlare Capital PartnersGreycroftNew Enterprise Associates (NEA)

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsLongwood FundNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsMedical Excellence CapitalDeerfield Management Company

HealthtechSan Mateo, US

Victor Colunga(Executive Officer)Stephen G. Dilly, Jr.(Executive Officer, Director)

BoardJoonkyoo (Anthony) Yun(Director)Stacey D. Seltzer(Director)Patrick Enright(Director)

Board seatJames Tananbaum· per SEC Form D · $80M raise · filed Mar 2015

Co-investorsQiming Healthcare

HealthtechSan Francisco, US

June Lee(Executive Officer, Director)

BoardJames Tananbaum(Director)

Board seatMichael RomeVikram Bajaj· per SEC Form D · $60M raise · filed Mar 2021

Co-investorsSamsara BioCapital

HealthtechSouth San Francisco, US

Zachary Sweeney(Executive Officer, Director)

Board seatJames TananbaumVikram Bajaj· per SEC Form D · $50M raise · filed Nov 2021

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)

Board seatMichael Rome· per SEC Form D

Co-investorsNextech InvestJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechSan Francisco, US

Uri Lopatin(Founder/CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)Elizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)

BoardJ. Jay Lobell(Director)

Board seatJames B. Tananbaum· per SEC Form D

Co-investorsY CombinatorKhosla Ventures

BiotechWoburn, US

Feng Xuan(Executive Officer, Director)Peng Yin(Director)John Wu(Executive Officer)Wen Chan(Director)Michael Natan(Executive Officer, Director)

BoardDavid Singer(Director)

Board seatVikram Bajaj· per SEC Form D

Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.

BiotechPhiladelphia, US

David Brand(Executive Officer, Director)Gregory Lumpkin(Executive Officer)

BoardRichard Kollender(Director)Martin Edwards(Director)Eric Bednarski(Director)Derek Ferguson(Director)

Board seatJames Tananbaum· per SEC Form D · $2M raise · filed Feb 2016

Co-investorsMVM Life Science Partners

BiotechCambridge, US

William C. Shakespeare(Director)

BoardIain Dukes(Executive Officer, Director)inCarl Gordon(Director)in

Board seatMichael Rome· per SEC Form D

Co-investorsLongitude CapitalNextech InvestOrbiMed

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)KEVIN F. MCLAUGHLIN(Executive Officer)MATTHEW L. SHERMAN(Executive Officer)

Co-investorsBessemer Venture PartnersLightstone VenturesLowercarbon CapitalSofinnova VenturesVenrockCollaborative Fund

BiotechBerkeley, US

Thomas Dubensky(Executive Officer)Dirk G. Brockstedt(Executive Officer)Stephen Isaacs(Executive Officer, Director)Jennifer Lew(Executive Officer)Gregory W. Schafer(Executive Officer)Gregory Schafer(Executive Officer)

Co-investorsFranklin TempletonOrbiMed

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

DAVID GRYSKA(Director)VICENTE ANIDO(Executive Officer, Director)MURRAY GOLDBERG(Director)ANAND MEHRA(Director)BRIAN LEVY(Executive Officer)GERALD CAGLE(Director)

Co-investorsAlta PartnersAvoro Capital AdvisorsOUP (Osage University Partners)Sofinnova Ventures

Co-investorsB Capital GroupFlare Capital Partners

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)Kamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBain Capital Life SciencesEcoR1 Capital

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas VentureFrazier Life SciencesScion Life SciencesThe Innovation SpacevenBio PartnersVersant Ventures

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalTruVenturo GmbHCTI Life Sciences Fund L.P.+3 more

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalSLVCSofinnova Ventures+2 more

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.

BiotechFremont, US

Michael Raab(Executive Officer, Director)Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)David Rosenbaum(Executive Officer)Jeremy Caldwell(Executive Officer)Mike Raabin

Co-investorsHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LPGeneral CatalystHongShan Capital GroupLAVLilly Asia VenturesOrbiMed+2 more

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)James Healy(Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Rafa?le Tordjman(Director)Martin Olin(Director)

Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsRA CapitalSofinnova Ventures

Co-investors5AM Ventures

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+3 more

New gene therapy treatments for people with serious, rare diseases.

BiotechBannockburn, US

James L'Italien(Executive Officer)Andrew F. Knudten(Executive Officer)Paul Manning(Director)Sukumar Nagendran(Executive Officer)Bong Koh(Director)Thomas Dee(Executive Officer)

Co-investorsPBM CapitalRA CapitalSofinnova Ventures

Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.

BiotechHouston, US

David M. Spencer(Executive Officer)Ken Moseley(Executive Officer)Thomas J. Farrell(Executive Officer, Director)Annemarie Moseley(Executive Officer)Joseph Senesac(Executive Officer)

BoardKevin M. Slawin(Executive Officer, Director)

Co-investorsRA CapitalRapha Capital Management, LLC

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)Christine Bellon(Executive Officer)Kyle Kuvalanka(Executive Officer)

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-Prime CapitalNextech InvestRA Capital

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio PartnersVida Ventures

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsAdvent Life SciencesEcoR1 CapitalMedicxiOberland CapitalScion Life SciencesVida Ventures+1 more

Color Health operates a nationwide virtual cancer clinic delivering oncologist-led care, screening, and treatment management for employer, union, health plan, and public sector populations.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Othman Laraki(CEO)

Co-investors8VCComcast VenturesCRV (Charles River Ventures)Dria VenturesHomebrewKindred Ventures+7 more

ConnectiveRx provides hub services, patient support, and patient affordability programs that help pharmaceutical manufacturers, healthcare providers, and patients access and stay on prescribed therapies.

Digital HealthHealthtechSaaS

Co-investorsGenstar

Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer.

BiotechHealthtechBurlingame, US

Richard A. Miller(Executive Officer, Director)Leiv Lea(Executive Officer)Terry G. Gould(Director)

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Director)

Co-investorsAvoro Capital AdvisorsOrbiMed

Clint Sever(Founder)in

Co-investorsDarwin CapitalDecheng CapitalDentsu VenturesPrime PartnersACME CapitalCAVU Consumer Partners+1 more

Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.

BiotechHealthtechNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)

Co-investorsAvoro Capital AdvisorsBay City CapitalVantagePoint Capital Partners

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Executive Officer, Director, Promoter)Peter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)

BoardRishi Gupta(Director)in

Co-investorsAV8 VenturesIllumina VenturesMenlo VenturesOpen Field CapitalOrbiMedOUP (Osage University Partners)+3 more

HealthtechMenlo Park, US

THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)Christopher M. Griffith(Executive Officer, Promoter)Luis C. Pena(Executive Officer, Promoter)Thomas G. Wiggans(Executive Officer, Director, Promoter)Eugene A. Bauer(Executive Officer, Director, Promoter)

Co-investorsAisling CapitalBay City CapitalCanaan PartnersNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.

AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US

Andreas Sundquist(Executive Officer, Director)Richard Daly(Executive Officer, Director)George Asimenos, PhD(Chief Product Officer)in

BoardMICHAEL GOLDBERG(Director)GEOFF DUYK(Director)KRISHNA YESHWANT(Director)in

Co-investorsClaremont Creek VenturesGV (Google Ventures)K9 VenturesUncork CapitalWireframe Ventures

BiotechSan Francisco, US

NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)

Co-investorsRA Capital

Element is a global provider of lab-based Testing, Inspection and Certification (TIC) services, including destructive and non-destructive material testing, product qualification testing, and certification of products and management systems.

Advanced ManufacturingEnterprise SoftwareNew Materials

Co-investors3i GroupMetaplanetProtocol LabsT. Rowe PriceVenrock

Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.

BiotechDeep TechHardwareMedical Devices

Co-investorsDraper AssociatesFusionRA CapitalTSVCVenrock

Everlywell offers at-home lab testing kits and virtual healthcare services across multiple wellness categories including daily health screening, digestive analysis, sexual health testing, and hormone monitoring.

Digital HealthHealthtechWellness & Fitness

Julia Cheek(Founder & CEO)

Co-investorsAnsa CapitalHalogen Ventures Management Company LlcNext Coast VenturesNextGen Venture PartnersPortfoliaThe Chernin Group (TCG Crypto)+3 more

Everlyhealth operates an at-home laboratory testing platform that enables consumers to monitor their health through biomarker analysis across multiple categories including daily health, digestive health, sexual health, and hormone health, with optional virtual care consultations.

ConsumerDigital HealthHealthtech

Co-investorsBreyer CapitalCerity Partners VenturesHalogen Ventures Management Company LlcLux CapitalNext Coast VenturesNextGen Venture Partners+2 more

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Martin Reese(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)

Co-investorsArtis VenturesMighty CapitalCasdin Capital

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)Liana M Guzman Weis(Executive Officer, Director)

BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in

Co-investors7wire VenturesBessemer Venture PartnersCorewell Health VenturesDefine VenturesHabitat PartnersSeae Ventures+2 more

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas VentureF-Prime CapitalInvus

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.

AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB

Peter Donnelly

Co-investorsF-Prime Capital

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)

Co-investorsB Capital GroupB4 CapitalBlue Lion GlobalFlare Capital PartnersLG Technology VenturesMcKesson Ventures+6 more

Co-investorsFlare Capital Partners

US direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.

Jack Abraham(Co-founder)in

Co-investors7GC & Co8VCA-Rod CorpAtomicBrentwood AssociatesCAVU Consumer Partners+16 more

identifeye health develops an automated retinal imaging platform that captures high-quality fundus images at the point-of-care and integrates into clinical workflows.

AI & Machine LearningDigital HealthMedical Devices

BiotechBoston, US

Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)

BoardOtello Stampacchia(Director)in

Co-investorsAtlas VentureBiotechnology Value FundOmega FundsOrbiMedRTW Investments L.P.

BiotechBoulder, US

Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)

BoardRoger Wyse(Director)inBryan Roberts(Director)

Co-investorsiGlobe PartnersKorysOak HC/FTOMX VenturesPaladin Capital GroupSpruce Capital Partners+3 more

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)

BoardRobert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)HOF CapitalSoftBank Vision FundBezos Expeditions+5 more

Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.

BiotechBoston, US

James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)

Co-investorsBay City CapitalCycad Group LLCNXT Ventures

Co-investorsRA Capital

Jade Biosciences is a clinical-stage biotech company developing antibody-based therapies for autoimmune diseases, with a lead candidate (JADE101) targeting the cytokine APRIL for the treatment of immunoglobulin A nephropathy (IgAN).

BiotechHealthtech

Co-investorsFrazier Life Sciences

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

Stuart Poulton(Executive Officer)Michael Mano(Executive Officer)Reshma Rangwala(Executive Officer)Richard Paulson(Executive Officer, Director)Stephen Mitchener(Executive Officer)Michael Mason(Executive Officer)

Co-investorsAvoro Capital AdvisorsHEALTHCARE ROYALTY PARTNERS

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsNextech InvestAlexandriaLilly Asia VenturesLongwood Fund

Kira Pharmaceuticals develops therapies targeting the complement system for patients with complement-mediated autoimmune and inflammatory diseases across areas including hematology, nephrology, neurology, dermatology and ophthalmology.

BiotechHealthtech

Wenru Song(Founder)

Co-investorsQuan CapitalVivo CapitalIkarian Capital

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

Shankar Ramaswamy(Co-Founder, Chairman & CEO)Roger Jeffs(Co-Founder & Vice Chairman)Fraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)Shankar Ramaswamy, M.D.(Founder)inMichele Stone(Chief Scientific Officer)Katherine Eade(Chief Legal Officer)

Co-investorsPatient Square CapitalPremji InvestAmplo VenturesBluebird VenturesJDRF T1D FundNarya Capital+2 more

Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.

BiotechHealthtechThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)

BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)

Co-investorsAccess BiotechnologyKern Capital, LLCSanofi Ventures5AM VenturesWestlake Village BioPartners

Lucira Health manufactures portable diagnostic devices that connect to smartphones to test bodily fluids for infectious diseases, enabling rapid results outside of clinical settings.

BiotechHealthtechMedical DevicesEmeryville, US

Debkishore Mitra(Founder)inJohn R. Waldeisen(Director)

BoardErik T. Engelson(Executive Officer, Director)Justin Butler(Director)Tuff Yen(Director)Steve Tablak(Director)

Co-investors11.2 CapitalShangBay Capital LLCY CombinatorOS Fund

Lyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors.

BiotechHealthtech

Co-investorsARCH Venture PartnersvenBio Partners8VCAxial VC

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

BiotechDeep TechMedical DevicesBrisbane, US

Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)

BoardUrshit Parikh(Director)

Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONDecheng CapitalMayfield FundMission Bay Capital+9 more

Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.

BiotechFemTechHealthtechSouth San Francisco, US

Maneesh Jain(Executive Officer, Director, Promoter)inStephen Quake(Director)

BoardLisa Iverson(Director)Ursheet Parikh(Director)inMin Cui(Director)inSamir Kaul(Director)in

Co-investorsDecheng CapitalMayfield FundPortfoliaGeneral CatalystKhosla Ventures

BiotechSouth San Francisco, US

Tassos Anastasios Gianakakos(Executive Officer, Director)

BoardKevin Starr(Director)inCharles Homcy(Director)Mark Perry(Director)Katherine Bowdish(Director)

Co-investorsKhosla VenturesThird Rock Ventures

MyOme uses whole genome sequencing and bioinformatics to analyze a single patient sample and produce clinically actionable reports, offering both proactive health tests (such as polygenic risk scores and medication response) and diagnostic tests for rare disease.

BiotechDigital HealthHealthtech

Co-investorsHOF CapitalSamsung Next

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)Darrin Miles(Chief Executive Officer)Philip Komarnitsky(Chief Medical Officer)Tanja Weber(Chief Business Officer)

Co-investorsVersant VenturesSixty Degree CapitalCowen Healthcare InvestmentsGoldman Sachs

BiotechSouth San Francisco, US

Jin-Long Chen(Executive Officer, Director)William J. Rieflin(Executive Officer, Director)David V. Goeddel(Director)

BoardPeter Svennilson(Director)inMark Leschly(Director)David Schnell(Director)

Co-investorsProspect Venture PartnersThe Column Group

Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)Mark Goldsmith(Director)

Co-investorsBain Capital Life SciencesEcoR1 CapitalSofinnova VenturesThe Column Group

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)

BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)

Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPGlobal BioAccess FundGreatPoint VenturesJeito Capital+6 more

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.

BiotechHealthtechMedical DevicesYardley, US

Per Djupesland(Executive Officer, Director)Michele Janis(Executive Officer)Peter Miller(Executive Officer, Director)Terrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)

BoardKlaas De Boer(Director)

Co-investorsMVM Life Science Partners

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)Steven M. Altschuler(Director)John Curnutte(Director)

BoardBobby Gaspar(Scientific Founder)in

Co-investorsAlbionVCF-Prime CapitalUCL Technology FundAgent CapitalBaillie GiffordORI Capital+1 more

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBain Capital Life SciencesKurma PartnersvenBio Partners

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

Chengzao Sun(Founder)Sandeep Somani(Founder)

Co-investorsQuan CapitalRA Capital

Quantum-Si develops benchtop instruments (Platinum and Platinum Pro) for single-molecule, single-amino-acid resolution protein sequencing, used to identify proteins, protein variants, and post-translational modifications.

BiotechHardwareMedical Devices

Co-investorsHighCape CapitalYuanBio Venture Capital

Co-investorsMedicxi

RayThera develops small molecule therapies targeting unmet needs in immunology.

BiotechHealthtech

Co-investorsOrbiMed

Redesign Health is a venture capital and applied technology platform that builds and invests in next-generation healthcare companies using AI-native strategies.

AI & Machine LearningDigital HealthHealthtech

Co-investorsCVS Health VenturesDeclaration PartnersForerunner VenturesMantis CapitalRiverPark VenturesSamsung Next

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.

BiotechHealthtechBoston, US

Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)inTodd Foley(Director)

Co-investorsHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMedThird Rock Ventures

Sangamo is a genomic medicine company using its proprietary zinc finger technology to develop gene therapies aimed at curing severe diseases, with a focus on neurology and rare disorders.

BiotechMedical Devices

Co-investorsCalifornia Technology VenturesFoothill VenturesRidgeback Capital

Signant Health provides eClinical technology and services for clinical trial data collection, including electronic data capture, patient and site data solutions, and scientific and operational support.

Digital HealthHealthtechSaaS

Co-investorsGenstar

Good Lab is a brand and design agency serving early-stage, rapid-growth ventures in health, wellness, environmental sciences, and life sciences.

Creator EconomyMarketing Tech

John Montgomery(Founder)in

Slate Medicines is a clinical-stage biotechnology company.

BiotechMedical DevicesBoston, US

Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)Gregory Frank Oakes(Executive Officer)Gregory Oakes(Chief Executive Officer and Board Director)

BoardTim Lohoff(Director)Cindy Xiong(Director)

Co-investorsRA Capital

SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.

BiotechDeep TechHealthtechBoulder, US

Larry Gold(Director)Larry Gold PhD(Founder)inDaniel Muehl(Executive Officer)Byron Hewett(Executive Officer, Director)

BoardCharles Lillis(Director)Youichi Yabuuchi(Director)

Co-investorsKhosla VenturesCasdin Capital

HealthtechSan Diego, US

Thomas Watlington(Executive Officer, Director)Mark Spring(Executive Officer)

BoardBobby Kandaswamy(Director)Timothy Wollaeger(Director)Kenneth Buechler(Director)Walter Lim(Director)

Co-investorsSanderling VenturesIntel CapitalQualcomm Ventures

Co-investorsF-Prime CapitalQiming Venture Partners

Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.

Digital HealthHealthtechMedical DevicesSeattle, US

Ben Casavant(Co-Founder and Chief Executive Officer)Erwin Berthier(Co-Founder and Chief Technology Officer)Alan Levy(Director)

BoardElizabeth Hambrecht(Director)Paul Conley(Director)in

Co-investorsJ2 VenturesOMX VenturesRA CapitalTechstarsVenture Capital Investment ManagementVertical Venture Partners

Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.

Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US

Ian Laffey(Founder)inSacha Lévy(Founder)in

Co-investorsY CombinatorAntlerFirst Round CapitalLux Capital

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)

BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in

Co-investorsAndreessen HorowitzVida Venturesabrdn plcBiotechnology Value FundHillhouse InvestmentOmega Funds+1 more

Thyme has partnered with Altruist to create Hazel, an AI product for wealth management professionals.

AI & Machine LearningEnterprise SoftwareFintechSan Francisco, US

Daniel Lantz(Founder)inFernando San Martin(Founder)in

Co-investorsY CombinatorAlleyCorpConcord Health PartnersCVS Health VenturesFrist Cressey VenturesHumana+1 more

Thyme Care develops software to enhance care coordination and outcomes for cancer patients.

Digital HealthHealthtechNashville, US

Robert Green(Executive Officer, Director)Robin Shah(Executive Officer, Director)inBobby Green(Founder)in

BoardBrian Belsky(Director)inElizabeth Canis(Director)inBrenton Fargnoli(Director)in

Co-investorsAlleyCorpAndreessen HorowitzCorewell Health VenturesCVS Health VenturesEcho Health VenturesFrist Cressey Ventures+4 more

Co-investorsLAVLilly Asia VenturesNextech InvestSv Tech Ventures, Inc.

uniQure is a gene therapy company developing treatments for Huntington's disease and other serious medical conditions.

BiotechHealthtech

Matthew Kapustain

Co-investorsAdvent Life SciencesHEALTHCARE ROYALTY PARTNERS

Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.

Malvern, US

Co-investorsAMR Action FundBioAdvance